Exorcising Martin Shkreli’s ghost, KaloBios steps out of Ch. 11 and back into the biotech business
Six months after Martin Shkreli’s brief, turbulent role as the controversial savior of the troubled KaloBios ended in Chapter 11 and near extinction, new CEO Cameron Durrant is turning the last page on that chapter of pulp fiction drama.
This morning KaloBios says it has emerged from bankruptcy with $14 million in financing, a newly reorganized board and a completed deal with Savant Neglected Diseases to develop benznidazole for the treatment of rare cases of Chagas disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.